NCT04839185View on ClinicalTrials.gov

Placental Lesions in Fetal Growth Restrictions

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

October 6, 2021

Study Completion Date

October 6, 2021

Conditions
Fetal Growth Retardation
Interventions
DRUG

Ferumoxytol infusion

"Ferumoxytol will be administered intravenously, by infusion, over 30 minutes. It will be used a contrast agent for MRI imaging to detect placental lesions in fetal growth restriction.~Dose will be 255 mg in 50 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Ferumoxytol/Feraheme will be administered only once, in one infusion of 255 mg to each subject."

PROCEDURE

MRI scan

The MRI scanning procedure will last for approximately 60 minutes.

Trial Locations (1)

53715

University of Wisconsin-Madison, Madison

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of Wisconsin, Madison

OTHER